Grace Therapeutics (GRCE) Current Assets (2017 - 2026)

Grace Therapeutics has disclosed Current Assets across 10 years of filings, most recently posting $14.3 million for Q2 2026.

• In Q2 2026, Current Assets fell 30.17% year-over-year to $14.3 million; the TTM figure through Jun 2026 stood at $14.3 million (down 30.17% YoY), while the FY2026 annual figure was $17.4 million, down 23.48% from the prior year.
• Current Assets came in at $14.3 million for Q2 2026 at Grace Therapeutics, down from $17.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $45.3 million in Q1 2022 to a low of $11.9 million in Q4 2024.
• Average Current Assets over 5 years is $25.0 million, with a median of $23.2 million recorded in 2023.
• Year-over-year, Current Assets sank 55.59% in 2024 and soared 60.91% in 2025.
• Over 5 years, Current Assets stood at $33.4 million in 2022, then retreated by 19.58% to $26.9 million in 2023, then slumped by 55.59% to $11.9 million in 2024, then jumped by 60.91% to $19.2 million in 2025, then dropped by 25.39% to $14.3 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $14.3 million in Q2 2026, $17.4 million in Q1 2026, and $19.2 million in Q4 2025.